These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22534863)

  • 1. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
    Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T
    J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
    Takami M; Ihara F; Motohashi S
    Front Immunol; 2018; 9():2021. PubMed ID: 30245690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.
    Ishibashi F; Sakairi Y; Iwata T; Moriya Y; Mizobuchi T; Hoshino H; Yoshida S; Hanaoka H; Yoshino I; Motohashi S
    Clin Immunol; 2020 Jun; 215():108457. PubMed ID: 32387537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
    Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.
    Toyoda T; Kamata T; Tanaka K; Ihara F; Takami M; Suzuki H; Nakajima T; Ikeuchi T; Kawasaki Y; Hanaoka H; Nakayama T; Yoshino I; Motohashi S
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
    Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
    J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of leukotriene B4 12-hydroxydehydrogenase in α-galactosylceramide-pulsed dendritic cell therapy for non-small cell lung cancer.
    Tanaka K; Kanesaka Y; Takami M; Suzuki A; Hosokawa H; Onodera A; Kamata T; Nagato K; Nakayama T; Yoshino I; Motohashi S
    Biochem Biophys Res Commun; 2018 Nov; 506(1):27-32. PubMed ID: 30336981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer.
    Kurosaki M; Horiguchi S; Yamasaki K; Uchida Y; Motohashi S; Nakayama T; Sugimoto A; Okamoto Y
    Cancer Immunol Immunother; 2011 Feb; 60(2):207-15. PubMed ID: 20978887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer T cell activation increases iNOS
    Paul S; Chhatar S; Mishra A; Lal G
    J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
    Singh AK; Shukla NK; Das SN
    Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of NKT cells in cancer immunotherapy.
    Bae EA; Seo H; Kim IK; Jeon I; Kang CY
    Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
    Fallarini S; Paoletti T; Panza L; Lombardi G
    Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
    Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
    Front Immunol; 2019; 10():352. PubMed ID: 30881361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.